← BioScience Health Innovations, Inc. (BHIC) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
BioScience Health Innovations, Inc. (BHIC)
Services-Computer Processing & Data Preparation · market cap $47M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| GBP510 adjuvanted with Alum (RBD 10μg/dose) - Stage 1 | Phase 2 | COVID-19 (Healthy Volunteers) |
| GBP510 adjuvanted with AS03 | Phase 3 | COVID-19 |
| GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose) | Phase 3 | Covid19 |
Price & technical context
3-month
+0.0%
6-month
-92.3%
12-month
-92.3%
52-wk range
$4.00–$52.00
vs 50-day MA
+0.0%
vs 200-day MA
-85.3%
Realized vol
256.5%
Max drawdown
-92.3%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BHIC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.